TOKYO - Takeda Pharmaceutical Co. said Wednesday it will start developing a drug to treat people infected with the fast-spreading new coronavirus and aims to commercialize it in as early as nine months.The Japanese drug maker will use blood taken from people who have recovered from COVID-19, a pneumonia-like respiratory disease caused by the virus that has infected over 90,000 people around the world and killed more than 3,000.Takeda said it plans to develop "a type of plasma derived-therapy that has previously been shown to be effective in the treatment of severe acute viral respiratory i…READ FULL ARTICLE
